Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury

Fasiglifam (TAK-875), a Free Fatty Acid Receptor 1 (FFAR1) agonist in development for the treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects. A mechanistic investigation described in this manuscript focused on the inhibition of bile acid (BA) transporter...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolenski, Francis S., Zhu, Andy Z. X., Johnson, Mike, Yu, Shaoxia, Moriya, Yuu, Ebihara, Takuya, Csizmadia, Vilmos, Grieves, Jessica, Paton, Martin, Liao, Mingxiang, Gemski, Christopher, Pan, Liping, Vakilynejad, Majid, Dragan, Yvonne P., Chowdhury, Swapan K., Kirby, Patrick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Fasiglifam and Bile Acid Homeostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414857/
https://www.ncbi.nlm.nih.gov/pubmed/28108665
http://dx.doi.org/10.1093/toxsci/kfx018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414857/
https://www.ncbi.nlm.nih.gov/pubmed/28108665
http://dx.doi.org/10.1093/toxsci/kfx018

Ejemplares similares